Human VEGFR2/KDR/Flk-1 Antibody

Catalog #: MAB3573
6 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB3573-SP
MAB3573-500
MAB3573-100

Product Details

Citations (6)

Supplemental Products

Reviews

Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human VEGFR2/KDR/Flk-1 Antibody Summary

Species Reactivity

Human

Specificity

Detects human VEGFR2/KDR/Flk-1 in ELISAs and Western blots. In Western blots, no cross-reactivity with recombinant human (rh) VEGFR1, rhVEGFR3, or recombinant mouse VEGFR2 is observed.

Source

Monoclonal Mouse IgG₁ Clone # 89109

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

S. frugiperda insect ovarian cell line Sf 21-derived recombinant human VEGFR2/KDR/Flk-1
Ala20-Glu764
Accession # P35968

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

Recombinant Human VEGFR2/KDR/Flk-1 Fc Chimera (Catalog # 357-KD)
under non-reducing conditions only. It is recommended to use Goat Anti-Human VEGFR2/KDR/Flk‑1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF357).

Human VEGFR2/KDR Sandwich Immunoassay

Recommended Concentration

Reagent

ELISA Capture (Matched Antibody Pair)

2-8 µg/mL

Use in combination with:

Detection Reagent: Human VEGFR2/KDR/Flk‑1 Biotinylated Antibody (Catalog # BAF357)

Standard: Recombinant Human VEGFR2/KDR Fc Chimera Protein (Catalog # 357-KD)

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR2/KDR/Flk-1

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. VEGFR2 cDNA encodes a 1356 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGFR2 is composed of a 745 aa residue extracellular domain, a 25 aa residue transmembrane domain and a 567 aa residue cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

References

Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.

Long Name

Vascular Endothelial Growth Factor Receptor 2

Entrez Gene IDs

3791 (Human); 16542 (Mouse)

Alternate Names

CD309 antigen; CD309; EC 2.7.10; EC 2.7.10.1; Fetal liver kinase 1; fetal liver kinase-1; Flk1; Flk-1; FLK1tyrosine kinase growth factor receptor; KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; KRD1; Ly73; Protein-tyrosine kinase receptor flk-1; soluble VEGFR2; vascular endothelial growth factor receptor 2; VEGF R2; VEGFR; VEGFR2; VEGFR-2

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human VEGFR2/KDR/Flk-1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

6 Citations: Showing 1 - 6
Filter your results:

Filter by:

Discovering Small Molecule Ligands of Vascular Endothelial Growth Factor That Block VEGF–KDR Binding Using Label-Free Microarray-Based Assays
Authors: James P. Landry, Yiyan Fei, Xiangdong Zhu, Yaohuang Ke, Guoliang Yu, Pierre Lee
ASSAY and Drug Development Technologies
Rhodocetin-alpha beta –induced Neuropilin-1–cMet Association Triggers Restructuring of Matrix Contacts in Endothelial Cells
Authors: Stephan Niland, Bartosz Ditkowski, Désirée Parrandier, Lise Roth, Hellmut Augustin, Johannes A. Eble
Arteriosclerosis, Thrombosis, and Vascular Biology
Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model.
Authors: Wen J, Fu AF, Chen LJ, Xie XJ, Yang GL, Chen XC, Wang YS, Li J, Chen P, Tang MH, Shao XM, Lu Y, Zhao X, Wei YQ
Int. J. Cancer, 2009-06-01;124(11):2709-18.
Species: Human
Sample Types: Cell Culture Supernates
Applications: Western Blot
Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells.
Authors: Meissner M, Reichenbach G, Stein M, Hrgovic I, Kaufmann R, Gille J
Cancer Res., 2009-02-17;69(5):1976-84.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot
Interaction with human stromal cells enhances CXCR4 expression and engraftment of cord blood Lin(-)CD34(-) cells.
Authors: Kobune M, Kawano Y, Takahashi S, Takada K, Murase K, Iyama S, Sato T, Takimoto R, Niitsu Y, Kato J
Exp. Hematol., 2008-06-17;36(9):1121-31.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
Authors: Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, Rosenfeld R, Davy E, Graham K, Jacobsen F, Stevenson S, Ho J, Chen Q, Hartmann T, Michaels M, Kelley M, Li L, Sitney K, Martin F, Sun JR, Zhang N, Lu J, Estrada J, Kumar R, Coxon A, Kaufman S, Pretorius J, Scully S, Cattley R, Payton M, Coats S, Nguyen L, Desilva B, Ndifor A, Hayward I, Radinsky R, Boone T, Kendall R
Cancer Cell, 2004-11-01;6(5):507-16.
Species: Human
Sample Types: Recombinant Protein
Applications: ELISA Development